Browse Careers
Browse Investors

Bard Announces Issuance Of ePTFE Vascular Patent

MURRAY HILL, N.J.--(BUSINESS WIRE)--Aug. 20, 2002--C. R. Bard, Inc. (NYSE:BCR - News) announced that the U.S. Patent Office today issued a patent to Dr. David Goldfarb for ePTFE (expanded polytetrafluoroethylene) vascular applications.

Dr. Goldfarb has licensed his rights exclusively to Bard's wholly owned subsidiary, IMPRA, Inc.

ePTFE is used in vascular prosthetic applications, including grafts, which are devices that are commonly used to surgically bypass diseased arteries or to provide blood access for hemodialysis. In addition, ePTFE can be used to cover stents for peripheral and coronary applications and in endovascular devices to treat abdominal aortic aneurysms. It is readily accepted by body tissue, pliable and easily sutured. It has an excellent history as an implant material in many applications.

William H. Longfield, Bard's chairman and chief executive officer, stated, "The issuance of this patent provides Bard with broad and pre-eminent intellectual property rights to ePTFE technology. We believe that the establishment of these rights represents the successful completion of a critical step in our strategy of leadership in the peripheral vascular market."

The way for the patent issuance was cleared last year when, after a series of judicial and administrative rulings upholding Dr. Goldfarb's position, the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the Board of Patent Appeals and Interferences of the United States Patent and Trademark Office that awarded priority of inventorship to Dr. Goldfarb.

C. R. Bard, Inc., ( headquartered in Murray Hill, New Jersey, is a leading multinational developer, manufacturer and marketer of health care products in the fields of vascular, urology, oncology and surgical specialty products.

This press release contains forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Please refer to our June 30, 2002, Form 10-Q for a statement with regard to forward-looking statements, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.

     C. R. Bard, Inc.
     Investor Relations:
     Todd C. Schermerhorn, 908/277-8139


Primary Media Relations Contact

Scott Lowry
Vice President and Treasurer
C. R. Bard, Inc.
730 Central Avenue
Murray Hill, NJ 07974

Tel: 908-277-8365